glp-1 and mash Semaglutide Receives FDA Approval for Treatment of Beyond glucagon-like peptide-1: The promise

Gastrointestinal hormones and the dialogue between gut and brain

Advantages: Localized delivery to target tissue (skin, scalp) Non-invasive Lower systemic exposure Well-tolerated with established safety record in cosmeceuticals Limitations: Limited dermal penetration (molecular weight ~340 Da near the cutoff for transdermal absorption) No systemic anti-aging or anti-inflammatory effects Efficacy dependent on formulation vehicle (liposomal carriers significantly improve penetration) GHK-Cu Injection (Subcutaneous) GHK-Cu injection is explored in research settings for systemic administration

Reactive oxygen species in cardiovascular disease

Access continuous support to stay on track with your goals